SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.870
+0.060 (3.31%)
At close: May 30, 2025, 4:00 PM
1.979
+0.109 (5.84%)
After-hours: May 30, 2025, 7:07 PM EDT
SAB Biotherapeutics Employees
SAB Biotherapeutics had 63 employees as of December 31, 2024. The number of employees increased by 6 or 10.53% compared to the previous year.
Employees
63
Change (1Y)
6
Growth (1Y)
10.53%
Revenue / Employee
$5,997
Profits / Employee
-$544,069
Market Cap
17.93M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63 | 6 | 10.53% |
| Dec 31, 2023 | 57 | 1 | 1.79% |
| Dec 31, 2022 | 56 | -83 | -59.71% |
| Dec 31, 2021 | 139 | 53 | 61.63% |
| Dec 31, 2020 | 86 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SABS News
- 22 days ago - SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewsWire
- 2 months ago - SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewsWire
- 4 months ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga
- 4 months ago - SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - GlobeNewsWire
- 4 months ago - SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy - GlobeNewsWire
- 7 months ago - SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 9 months ago - SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewsWire